» Articles » PMID: 26556984

Inflammatory Status in Human Hepatic Cirrhosis

Overview
Specialty Gastroenterology
Date 2015 Nov 12
PMID 26556984
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

This review focuses on new findings about the inflammatory status involved in the development of human liver cirrhosis induced by the two main causes, hepatitis C virus (HCV) infection and chronic alcohol abuse, avoiding results obtained from animal models. When liver is faced to a persistent and/or intense local damage the maintained inflammatory response gives rise to a progressive replacement of normal hepatic tissue by non-functional fibrotic scar. The imbalance between tissue regeneration and fibrosis will determine the outcome toward health recovery or hepatic cirrhosis. In all cases progression toward liver cirrhosis is caused by a dysregulation of mechanisms that govern the balance between activation/homeostasis of the immune system. Detecting differences between the inflammatory status in HCV-induced vs alcohol-induced cirrhosis could be useful to identify specific targets for preventive and therapeutic intervention in each case. Thus, although survival of patients with alcoholic cirrhosis seems to be similar to that of patients with HCV-related cirrhosis (HCV-C), there are important differences in the altered cellular and molecular mechanisms implicated in the progression toward human liver cirrhosis. The predominant features of HCV-C are more related with those that allow viral evasion of the immune defenses, especially although not exclusively, inhibition of interferons secretion, natural killer cells activation and T cell-mediated cytotoxicity. On the contrary, the inflammatory status of alcohol-induced cirrhosis is determined by the combined effect of direct hepatotoxicity of ethanol metabolites and increases of the intestinal permeability, allowing bacteria and bacterial products translocation, into the portal circulation, mesenteric lymph nodes and peritoneal cavity. This phenomenon generates a stronger pro-inflammatory response compared with HCV-related cirrhosis. Hence, therapeutic intervention in HCV-related cirrhosis must be mainly focused to counteract HCV-immune system evasion, while in the case of alcohol-induced cirrhosis it must try to break the inflammatory loop established at the gut-mesenteric lymph nodes-peritoneal-systemic axis.

Citing Articles

Association of Systemic Inflammation Response Index with Short-Term All-Cause Mortality in Decompensated Liver Cirrhosis Patients.

Cheng J, Ju H, Wang G, He C, Wang W J Inflamm Res. 2024; 17:8985-8995.

PMID: 39583863 PMC: 11583772. DOI: 10.2147/JIR.S476743.


New insights into potential biomarkers and their roles in biological processes associated with hepatitis C-related liver cirrhosis by hepatic RNA-seq-based transcriptome profiling.

Nasr Azadani H, Toosi M, Shahmahmoodi S, Nejati A, Rahimi H, Farahmand M Virus Res. 2024; 349:199457.

PMID: 39216827 PMC: 11415974. DOI: 10.1016/j.virusres.2024.199457.


COVID-19 in patients with pre-existing chronic liver disease - predictors of outcomes.

Walia D, Saraya A, Gunjan D World J Virol. 2023; 12(1):30-43.

PMID: 36743659 PMC: 9896592. DOI: 10.5501/wjv.v12.i1.30.


Liver Fibrosis and Hearing Loss in an Older Mediterranean Population: Results from the Salus in Apulia Study.

Tatoli R, Tirelli S, Lampignano L, Castellana F, Bortone I, Zupo R J Clin Med. 2022; 11(23).

PMID: 36498787 PMC: 9736605. DOI: 10.3390/jcm11237213.


Cytotoxic T Cell Expression of Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) in Viral Hepatitis C-Mediated Hepatocellular Carcinoma.

Hammad R, Aglan R, Mohammed S, Awad E, Elsaid M, Bedair H Int J Mol Sci. 2022; 23(20).

PMID: 36293412 PMC: 9604124. DOI: 10.3390/ijms232012541.


References
1.
. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010; 53(3):397-417. DOI: 10.1016/j.jhep.2010.05.004. View

2.
Sreenarasimhaiah J, Jaramillo A, Crippin J, Lisker-Melman M, Chapman W, Mohanakumar T . Lack of optimal T-cell reactivity against the hepatitis C virus is associated with the development of fibrosis/cirrhosis during chronic hepatitis. Hum Immunol. 2003; 64(2):224-30. DOI: 10.1016/s0198-8859(02)00781-4. View

3.
Starkel P, De Saeger C, Strain A, Leclercq I, Horsmans Y . NFkappaB, cytokines, TLR 3 and 7 expression in human end-stage HCV and alcoholic liver disease. Eur J Clin Invest. 2010; 40(7):575-84. DOI: 10.1111/j.1365-2362.2010.02295.x. View

4.
Papp M, Vitalis Z, Altorjay I, Tornai I, Udvardy M, Harsfalvi J . Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. Liver Int. 2011; 32(4):603-11. DOI: 10.1111/j.1478-3231.2011.02689.x. View

5.
Massonnet B, Delwail A, Ayrault J, Chagneau-Derrode C, Lecron J, Silvain C . Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation. Clin Exp Immunol. 2009; 158(1):115-24. PMC: 2759066. DOI: 10.1111/j.1365-2249.2009.04004.x. View